Drugs / SH1573
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04806659 | Aug 2020 → Aug 2023 | acute myeloid leukemia | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH1573 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04806659 ↗ |
| Action | Inhibit | “SH1573 is an IDH2 mutation inhibitor.” NCT04806659 ↗ |
| Route | Oral | “SH1573 capsules administered orally.” NCT04806659 ↗ |
| Target | IDH2 | “SH1573 is an IDH2 mutation inhibitor.” NCT04806659 ↗ |